Clinical outcomes with besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis due to potentially consequential pathogens

by Comstock TL, Morris TW, Gearinger LS, DeCory HH
Published 2014-04-01

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

by Silverstein BE, Morris TW, Gearinger LS, DeCory HH, Comstock TL
Published 2012-11-01

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility prof...

by Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW
Published 2011-09-01

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes

by Morris TW, Gearinger LS, Usner DW, Paterno MR, DeCory HH, Comstock TL, Haas W
Published 2011-09-01